Further studies demonstrated that Q9 protein is a target for anti-tumor immune surveillance, as CD8+ T-cell-deficient mice as well as β2 microglobulin and CD8-knockout mice were unable to reject Q9-bearing melanoma tumors. Here, CD8A is linked to neoplasm.